CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. It's no longer a question of simply creating treatment options and offering care services. As a result of the advent of new technologies and product offerings in other industries, healthcare customers have come to expect the same experience from healthcare companies. Considering that medical experts continue to discover advanced diseases that seek to threaten our very survival, it is the responsibility of companies in the healthcare sector to develop nuanced approaches to overcoming these ailments that simultaneously satisfy the customer and their expectations. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Viking Therapeutics Inc (NASDAQ:
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to invest and develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network. Although other companies seem to have lost their competitive edge, Premier has a proven track record of not only meeting their customer's demands, but doing so with ingenuity and skill.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) has had a momentous year, replete with strategic acquisitions, the formulation of collaborative partnerships, and technological developments. In light of all these exciting milestones, the Company provided investors with a corporate update at the tail-end of last week.
Earlier this month, the Company announced that they would be formally entering the cannabis clinic space. Premier's recent acquisition of Cloud Practice Inc has provided an underlying platform to help empower and streamline patient-doctor interaction. Whereas other clinics typically struggle with the labor-intensive process of onboarding patients, this will be done automatically with Premier's smart EMR.
In an attempt to focus their expansion efforts into global markets, Premier Health Group (OTC:PHGRF) (CSE:PHGI) recently announced a partnership with a major online healthcare company in China, 360 Health. The parent company, 360 Security Technology, is a leading online service company in China with a market capitalization of over $20 billion USD as of February 14, 2019. This provides an opportunity for our team of health care providers to play an essential role in providing general practitioner training virtually and on-site through medical seminars.
Viking Therapeutics Inc (VKTX), a clinal stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine diseases, announced in early January that its chief executive officer, Brian Lian, Ph.D., would deliver a corporate presentation at the 11th Annual Biotech Showcase held later in the month.
The Company's shares enjoyed a pre-market boost of 6.39% on Monday morning, with shares trading at $9.65 per share just before the opening bell.
AcelRx Pharmaceuticals Inc (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies, announced just before the end of January that the Company will present on DSUVIA ™ at the 41st Annual Boswick Burn and Wound Symposium later in February.
Paul Glad, Chairman of the Boswick Symposium, said, "we are pleased to welcome this presentation highlighting DSUVIA at this year's Symposium, and are excited to learn more about this novel, non-invasive analgesic. DSUVIA has the potential to provide a significant benefit to hospitalized burn patients suffering from moderate-to-severe pain, especially during wound dressing changes."
Bio Blast Pharma Ltd (ORPN) today announced the sale of its Trehalose clinical development programs to Seelos Therapeutics Inc. Per the details of the agreement, Seelos will pay Bioblast a payment of $3.5 million in two installments; $1.5 million payable upon closing of the sale and the other $2 million will be paid upon the first anniversary of the closing of the sale. Potential additional milestone payments of up to $17.0 million will be made upon completion of the clinical study and approval of a New Drug Application by the Food and Drug Administration, as well as royalties.
Following the announcement, Dalia Megiddo, Interim CEO of Bioblast, stated, "we have great faith in the efficacy of Trehalose for the treatment of several rare diseases. We are confident that Seelos will continue to develop the clinical programs skilfully for the benefit of the patients as well as for Bioblast's and Seelos' shareholders."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: